Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review
Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting right ventricular (RV) failure occur in many critical illnesses and may be associated with a worse prognosis. PH and RV failure may be difficult to manage: principles include maintenance of appropriate RV preload, augmentation of RV function, and reduction of RV afterload by lowering pulmonary vascular resistance (PVR). We therefore provide a detailed update on the management of PH and RV failure in adult critical care.
A systematic review was performed, based on a search of the literature from 1980 to 2010, by using prespecified search terms. Relevant studies were subjected to analysis based on the GRADE method.
Clinical studies of intensive care management of pulmonary vascular dysfunction were identified, describing volume therapy, vasopressors, sympathetic inotropes, inodilators, levosimendan, pulmonary vasodilators, and mechanical devices. The following GRADE recommendations (evidence level) are made in patients with pulmonary vascular dysfunction: 1) A weak recommendation (very-low-quality evidence) is made that close monitoring of the RV is advised as volume loading may worsen RV performance; 2) A weak recommendation (low-quality evidence) is made that low-dose norepinephrine is an effective pressor in these patients; and that 3) low-dose vasopressin may be useful to manage patients with resistant vasodilatory shock. 4) A weak recommendation (low-moderate quality evidence) is made that low-dose dobutamine improves RV function in pulmonary vascular dysfunction. 5) A strong recommendation (moderate-quality evidence) is made that phosphodiesterase type III inhibitors reduce PVR and improve RV function, although hypotension is frequent. 6) A weak recommendation (low-quality evidence) is made that levosimendan may be useful for short-term improvements in RV performance. 7) A strong recommendation (moderate-quality evidence) is made that pulmonary vasodilators reduce PVR and improve RV function, notably in pulmonary vascular dysfunction after cardiac surgery, and that the side-effect profile is reduced by using inhaled rather than systemic agents. 8) A weak recommendation (very-low-quality evidence) is made that mechanical therapies may be useful rescue therapies in some settings of pulmonary vascular dysfunction awaiting definitive therapy.
This systematic review highlights that although some recommendations can be made to guide the critical care management of pulmonary vascular and right ventricular dysfunction, within the limitations of this review and the GRADE methodology, the quality of the evidence base is generally low, and further high-quality research is needed.
KeywordsPulmonary Hypertension Right Ventricular Pulmonary Arterial Hypertension Levosimendan Right Ventricular Function
acute cor pulmonale
acute respiratory distress syndrome
cyclic adenosine 3',5'-cyclic monophosphate
cyclic guanosine 3',5'-cyclic monophosphate
chronic obstructive pulmonary disease
central venous pressure
extracorporeal membrane oxygenation
intensive care unit
intraaortic balloon pump
mitral valve replacement
pulmonary artery catheter
pulmonary arterial hypertension
pulmonary arterial occlusion pressure
pulmonary vascular resistance
right ventricular ejection fraction
right ventricular failure
mixed venous oxygen saturation
systemic vascular resistance
- V/Q mismatch
Causes of pulmonary hypertension and right ventricle failure in the ICU
Causes of pulmonary hypertension in ICU
Causes of RV failure in ICU
1) PAH (for example, preexisting PAH; PoPH (8.5% ESLD)
1) RV Pressure overload, pulmonary hypertension, any cause
2) Elevated LAP: RV pressure overload (left-sided myocardial infarction/cardiomyopathy; mitral regurgitation; pulmonary stenosis)
2) Reduced RV contractility
3) PH due to hypoxia: acute (for example, ARDS)/preexisting lung disease (for example, COPD, IPF)
RV infarction; sepsis; RV cardiomyopathy; myocarditis; pericardial disease; LVAD; after CPB; after cardiac surgery/transplantation
4) Thromboembolic (for example, acute PE; chronic (CTEPH); other causes of emboli (AFE, air, cement)
3) RV-volume overload
5) Mechanical (for example, increased Pplat - IPPV
Cardiac causes: tricuspid and pulmonary regurgitation; intracardiac shunts
PH is defined at right-heart catheterization in the outpatient setting, with resting mPAP exceeding 25 mm Hg, and a PVR greater than 240 dyn.s.cm-5 (3 Wood units) . At echocardiography, the presence of PH is suggested by the estimated RV systolic pressure (RVSP) exceeding 35 mm Hg (being severe if >50 mm Hg) (see later) , and the pulmonary arterial acceleration time (PAT) may be shortened . Pulmonary arterial hypertension (PAH) defines PH not due to left-heart disease, with PAOP <15 mm Hg or without echocardiographic evidence of increased left atrial pressure. The severity of PH may depend on the chronicity: the actual pulmonary artery pressure generated will increase with time as the RV hypertrophies.
RV dysfunction describes reduced RV contractility, which may be detected in several ways. At echocardiography, RV distention causes the intraventricular septum to deviate, with resulting paradoxic septal movement that impinges on LV function . RV function may be difficult to assess on echocardiography, especially in ventilated patients, and measurement of the descent of the RV base toward the apex (tricuspid annular systolic excursion, TAPSE) or RV fractional shortening may useful [12, 13]. Invasive monitoring may show a CVP exceeding the PAOP, or increasing CVP and PVR with a decreasing cardiac output (and mPAP may therefore decrease), and high right ventricular end-diastolic filling pressure is characteristic. By using an RV ejection fraction (RVEF) PAC, an increase in RV end-diastolic index and a reduction in RVEF are seen . We have defined RV failure to be the clinical result of RV dysfunction with the onset of hypotension or any resulting end-organ (for example, renal, liver, or gastrointestinal) dysfunction. Acute cor pulmonale (ACP) refers to acute right heart failure in the setting of acutely elevated PVR due to pulmonary disease [15, 16].
Pulmonary hypertension per se is frequently encountered in the ICU. It is commonly due to elevated pulmonary venous pressure in the setting of left-sided heart disease, or in patients with preexisting pulmonary vascular disease. It is well recognized after cardiothoracic surgery, in part related to the endothelial dysfunction seen with cardiopulmonary bypass (CPB) [17, 18]. PH is also associated with sepsis ; acute respiratory distress syndrome (ARDS) [20, 21, 22] (with associated acute RV failure in 10% to 25% of cases [23, 24]), and in up to 60% of patients after massive pulmonary embolism (PE) . PH is important to recognize in the ICU because its presence predicts increased mortality in these conditions [19, 23, 25, 26, 27, 28, 29, 30, 31] as well as after surgical procedures [32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]. Mortality from cardiogenic shock due to RV infarction (> 50%) exceeds that due to LV disease . We therefore thought that a systematic review of the current evidence for the management of PH, resulting RV dysfunction, and failure in adult patients in the ICU, would be a useful addition to the critical care literature.
The pulmonary circulation and pathophysiology of right ventricular failure
Local factors increasing pulmonary vascular tone
Factors increasing pulmonary vascular tone
Additional contributors to elevated PVR in ARDS
High pulmonary arterial pCO2/low pH
Vasoconstrictor: vasodilator imbalance
Low mixed venous pO2
High sympathetic tone; α-adrenoceptor agonism
Reduced NO, prostanoids 
High airway Pplat; gravity; increased flow (for example, one-lung ventilation)
Endothelial injury 
Relating to CPB:
Pulmonary vascular remodeling 
The diagnosis and management of acute pulmonary embolism (PE) warrants a specific mention, as it is a relatively common cause of acute RV failure in the ICU . Available therapies include thrombolysis and embolectomy, reducing the clot burden and acute mortality [74, 75], as well as reducing the longer-term risk of chronic thromboembolic PH . Given that more than half of related deaths occur within an hour of the onset of symptoms , effective supportive treatment of shock is paramount. Patients presenting with acute PE are risk stratified according to the effects of elevated RV afterload: hypotensive patients and those with elevated cardiac biomarkers or echocardiographic indices of RV strain, or both, are deemed at increased risk, and thrombolysis is indicated .
Management principles in pulmonary vascular dysfunction
1. Optimize volume status: avoid filling (± offload) if RV volume-overloaded
2. Augment CO
3. Reduce PVR
a) Use pulmonary vasodilators (preferably inhaled: less systemic hypotension and V/Q mismatch)
b) Treat reversible factors that may increase PVR
Metabolic state: correct anemia, acidosis, hypoxemia
Treat respiratory failure: treat hypoxia; limit Pplat by using lung-protective ventilatory strategies, but beware of high pCO2 increasing PVR
Reduce sympathetic overstimulation
4. Maintain adequate systemic vascular resistance (SVR): keep PVR well below SVR; use pressors if necessary
Materials and methods
Systematic review of ICU management of pulmonary vascular and RV dysfunction
Breakdown of clinical articles
Subtype of treatment for pulmonary vascular dysfunction
Number of studies in initial search
Number of suitable studies included in review
Results and Discussion
ICU management of pulmonary vascular and RV dysfunction
Management of PH with associated RV dysfunction in the ICU setting can be broken down into several treatment goals (Table 3). The first is to ensure adequate but not excessive RV filling or preload in the context of sufficient systemic blood pressure. The second goal is to maximize RV myocardial function, whether with inotropic support, rate or rhythm management, atrioventricular synchronization [82, 83], or by using mechanical devices. The third is to offload the right ventricle by reducing the PVR with pulmonary vasodilators as well as by ensuring adequate oxygenation, avoiding hypercapnia and acidosis, and by minimizing mechanical compression of pulmonary vessels (for example, due to excessive airway plateau pressure). The fourth is to maintain adequate aortic root pressure to allow sufficient right coronary arterial perfusion.
Management of volume and use of vasopressors
Systemic hypotension may relate to sepsis, overdiuresis, or progression of RV failure itself. Principles of volume management and vasopressor use are summarized.
With a normal RV, RV ejection fraction is usually primarily dependent on RV preload . In the setting of excessive myocardial distention (by fluids), wall tension increases according to the Frank-Starling mechanism, and muscle fiber length is increased, beyond a certain point at which ventricular function will fail. This situation may be precipitated sooner in the setting of PH and RV dysfunction, in which both hypo- and hypervolemia may reduce cardiac output [78, 85, 86]. In stable patients with PAH, high plasma volumes are associated with worse outcomes , but very few clinical studies have been performed in pulmonary vascular dysfunction, and the use of fluid loading remains controversial. Some animal studies show that fluids increase the cardiac index ; others show that they worsen shock by inducing RV ischemia or decreasing LV filling or both as the result of ventricular diastolic interdependence (due to an increase in RV volume) [89, 90, 91].
In acute cor pulmonale after massive PE, increased filling may be at least initially required [4, 92]. In observational studies in sepsis, up to 40% of patients have evidence of RV failure , predominantly due to primary RV dysfunction . These patients have a higher CVP at baseline  and are unable to augment stroke volume or perfusion pressure with fluid challenges alone, and so usually also require catecholamines [93, 94].
RV volume overload is a very important principle to recognize and treat promptly in RV failure. It may be identified by a rising V wave on the CVP trace, or by increased TR due to RV overdistention seen at echocardiography. In this situation of "backwards" heart failure, no further escalation of vasoactive agents is likely to be helpful (and may even be harmful), and management involves fluid removal (by using diuresis  or hemofiltration ) and avoidance of excessive RV afterload . Unmonitored fluid challenges are inadvisable in any setting of RV failure [98, 99].
GRADE RECOMMENDATION 1
Based on overall very-low-quality evidence (see Additional file 1), the following WEAK recommendation is made: Close monitoring of fluid status according to effects on RV function is recommended. Initial carefully monitored limited volume loading may be useful after acute PE, but may also worsen RV performance in some patients with pulmonary vascular dysfunction, and vasoactive agents may be required.
Pulmonary vascular properties of vasoactive agents
< 5 μg/kg/min
These include the catecholaminergic pressor, norepinephrine, and the noncatecholaminergic pressor phenylephrine. Their complex effects on the pulmonary circulation depend on the dose-related relative α- and β-adrenoreceptor stimulation as well as the degree and nature of RV dysfunction [99, 100]. All may potentially lead to tachydysrhythmias, diastolic dysfunction, myocardial ischemia, hyperlactatemia, and hypercoagulability .
Norepinephrine (NE) exerts its systemic vasopressor effects through α-1 agonism . Activation of these receptors also causes pulmonary vasoconstriction [102, 103], although the potential adverse effects on PVR are likely to occur only at high doses. Most evidence supporting this comes from animal studies in models of pulmonary vascular dysfunction, with NE at doses less than 0.5 μg/kg/min not increasing PVR . In persistent PH of the newborn, low-dose NE (0.5 μg/kg/min) reduces the PVR/SVR ratio . In adults with septic shock, higher doses of NE increase PVR/SVR, although without worsening RV performance . In patients with sepsis, PH, and associated RV dysfunction, NE increases SVR and improves the RV oxygen supply/demand ratio, although it does not increase RVEF and does increase PVR . Importantly, NE is positively inotropic through β-1 receptor agonism, thus improving RV/pulmonary arterial coupling, CO, and RV performance in studies of acute RV dysfunction due to PH [44, 89, 107, 108, 109], illustrated in a case report of acute PH after MVR surgery . In patients with chronic PH, NE reduces the PVR/SVR ratio, although it may not improve CI , which may relate to the "fixed" elevation in PVR .
Phenylephrine (PHE) is a direct α-agonist. Its use improves right coronary perfusion in RV failure  without causing tachycardia, although this benefit may be offset by worsening RV function due to increased PVR [100, 108, 111].
GRADE RECOMMENDATION 2
Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: NE may be an effective systemic pressor in patients with acute RV dysfunction and RV failure, as it improves RV function both by improving SVR and by increasing CO, despite potential increases in PVR at higher doses.
Nonsympathomimetic pressors: Vasopressin
Arginine vasopressin (AVP) causes systemic vasoconstriction via the vasopressinergic (V1) receptor. Experimental studies have revealed vasodilating properties at low doses that include pulmonary vasodilatation  through an NO-dependent mechanism via V1 receptors [113, 114]. This property manifests clinically as a reduction in PVR and PVR/SVR ratio [105, 115, 116]. AVP has also been used as a rescue therapy in patients during PH crises [117, 118, 119], in which untreated equalization of systemic and pulmonary pressures may be rapidly fatal. At low doses (0.03-0.067 U/min), it has been used safely in sepsis [105, 120, 121, 122, 123, 124], as well as in patients with acute PH and RV failure with hypotension after cardiac surgery [115, 116, 125, 126] and hypotension associated with chronic PH in several settings [117, 118, 127, 128].
AVP leads to a diuretic effect in vasodilatory shock , reduces the heart rate [105, 121, 130, 131, 132], and induces fewer tachyarrhythmias in comparison to NE [105, 131]. However, bradycardia  may be encountered at high clinical doses [134, 135]. AVP may cause dose-related adverse myocardial effects at infusion rates exceeding 0.4 U/min [134, 135], or even above 0.08 U/min in cardiogenic shock , which probably relate to direct myocardial effects, including coronary vasoconstriction [132, 137, 138, 139].
GRADE RECOMMENDATION 3
Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: In patients with vasodilatory shock and pulmonary vascular dysfunction, low-dose AVP may be useful in difficult cases that are resistant to usual treatments, including norepinephrine.
Inotropic augmentation of RV myocardial function
The next major goal is to improve RV myocardial function by using inotropes. The use of mechanical support is discussed later. For sympathomimetic agents, desirable cardiac β1 effects at lower doses maybe offset by chronotropic effects precipitating tachyarrhythmias , as well as worsening pulmonary vasoconstriction at higher doses  through α-agonism. Systemic hypotension may result from these agents and with phosphodiesterase inhibitors, which may necessitate co-administration of vasopressors.
Few clinical studies of these agents have been done in patients with PH and RV dysfunction. Dopamine increases CO, although it may cause a mild tachycardia in patients with PH  and increase the PVR/SVR ratio . Dopamine also tends to increase the heart rate and to have less-favorable hemodynamic effects in patients with cardiomyopathy than dobutamine , although it does not increase PVR at doses up to 10 μg/kg/min in animals with pulmonary vascular dysfunction . In patients with septic shock, PH, and RV dysfunction, dopamine improves CI without an increase in PVR . In the recent large randomized controlled study comparing dopamine with norepinephrine in patients with septic shock, dopamine increased arrhythmic events and, in patients with cardiogenic shock, increased the risk of death . In patients with primary RV dysfunction (without PH) due to septic shock, epinephrine improves RV contractility despite an 11% increase in mPAP . In animal studies, epinephrine reduces the PVR/SVR more than does dopamine . Isoproterenol has been used in RV failure primarily as a chronotrope after cardiac transplantation , although it may induce arrhythmias .
At clinical doses up to 5 μg/kg/min in heart failure, dobutamine increases myocardial contractility, reduces PVR and SVR, and induces less tachycardia than does dopamine . It improves RV performance in patients with PH at liver transplantation , after RV infarction, and is used in PAH exacerbations . It is synergistic with NO in patients with PH . Experimentally, dobutamine has favorable pulmonary vascular effects at lower doses [44, 154], although it leads to increased PVR, tachycardia, and systemic hypotension at doses exceeding 10 μg/kg/min . Given the adverse effects of systemic hypotension in these patients, it is important to anticipate and treat it with vasopressors when using dobutamine.
An inodilator increases myocardial contractility while simultaneously causing systemic and pulmonary vasodilatation. Inodilators include the phosphodiesterase (PDE) III inhibitors and levosimendan.
Several types of PDE are recognized: PDEIII usually deactivates intracellular cyclic adenosine monophosphate (cAMP), and PDE3 inhibitors therefore increase cAMP and augment myocardial contractility while dilating the vasculature [156, 157, 158]. The selective PDEIII inhibitors include enoximone, milrinone, and amrinone. They are most suited to short-term use because of tachyphylaxis , and mild tachycardia is common. Milrinone is most frequently used and has been shown to reduce pulmonary pressures and augment RV function in many studies in patients with pulmonary vascular dysfunction [160, 161, 162, 163, 164]. Enoximone improves RV function in pulmonary vascular dysfunction after cardiac surgery [165, 166] and in patients with decompensated chronic obstructive pulmonary disease (COPD) . Enoximone leads to fewer postoperative myocardial infarctions than does dobutamine [168, 169], which may relate to the resulting improved gas exchange when compared with dobutamine and GTN . Concerns regarding platelet aggregation with amrinone  do not appear to arise with enoximone  or milrinone after cardiac surgery [173, 174]. As with dobutamine, resulting reversible systemic hypotension means that coadministration with pressors is often necessary. Agents such as norepinephrine, phenylephrine or vasopressin are used, with the latter reducing PVR/SVR more than norepinephrine . PDEIII inhibitors may also improve RV function in chronic PH .
Nebulized milrinone is increasingly used to manage PH crises in several settings [176, 177, 178, 179]. Through pulmonary selectivity, it results in less systemic hypotension and less V/Q mismatch compared with intravenous use in patients with PH after mitral valve replacement surgery [177, 178]. The combination of milrinone-AVP reduces PVR/SVR and may be preferable to milrinone-NE in RV dysfunction .
Levosimendan sensitizes troponin-C to calcium and selectively inhibits PDE III, improving diastolic function and myocardial contractility without increasing oxygen consumption [180, 181, 182, 183]. It also acts as a vasodilator through calcium desensitization, potassium channel opening, and PDEIII inhibition . Levosimendan leads to a rapid improvement in hemodynamics, including reduction in PVR in patients with decompensated heart failure , with significant benefit on RV efficiency , with effects lasting several days . Levosimendan improves RV-PA coupling in experimental acute RV failure [187, 188, 189] more than dobutamine . These effects have been shown clinically with improvements in RV function and reduction in PVR in ischemic RV failure [190, 191, 192, 193, 194], ARDS , and after mitral valve replacement surgery [196, 197]. In chronic PH, repetitive doses reduce mPAP and PVR from baseline and improve SvO2 .
GRADE RECOMMENDATION 4
Based on low-moderate-quality evidence (see Additional file 1), a WEAK recommendation can be made that low-dose dobutamine (up to 10 μg/kg/min) improves RV function and may be useful in patients with pulmonary vascular dysfunction, although it may reduce SVR. Dopamine may increase tachyarrhythmias and is not recommended in the setting of cardiogenic shock (STRONG recommendation based on high-quality evidence level).
GRADE RECOMMENDATION 5
Based on mostly moderate-quality evidence (see Additional file 1), a STRONG recommendation can be made that PDE III inhibitors improve RV performance and reduce PVR in patients with acute pulmonary vascular dysfunction, although systemic hypotension is common, usually requiring coadmininstration of pressors. Based on low-quality evidence (see Additional file 1), a WEAK recommendation can be made that inhaled milrinone may be useful to minimize systemic hypotension and V/Q mismatch in pulmonary vascular dysfunction.
GRADE RECOMMENDATION 6
Based on mostly low-quality evidence (see Additional file 1), a WEAK recommendation can be made that levosimendan may be considered for short-term improvements in RV performance in patients with biventricular heart failure.
Reduction of right ventricular afterload
Agents used to reduce PVR in the ICU setting
Half-life (duration of action)
Potential adverse effects
Prostacyclin (Epoprostenol, Flolan)
Start at 1 ng/kg/min; titrate upward in 2-ng/kg/min increments according to effect
3-5 minutes (10 minutes)
Systemic hypotension, worsening oxygenation (increased V/Q mismatch), antiplatelet effect, headache, flushing, jaw pain, nausea, diarrhea
Similar to Flolan; also syncope (5%)
Sildenafil  (NB off-license use in hemodynamically unstable patients)
Low dose, 0.05 mg/kg; high dose, 0.43 mg/kg) (comes as 0.8 mg/ml)
Hypotension: caution if fluid depleted, severe LV-outflow obstruction, autonomic dysfunction. Hypoxemia due to V/Q mismatch. Common: headache, flushing, diarrhea, epistaxis, tremor. Rare but important: anterior ischemic optic neuropathy
50 μg/kg over 10 minutes followed by 0.375-0.75 μg/kg/min infusion
50-350 μg/kg/min, titrate up in 50 μg/kg/min increments
5-10 seconds (2 minutes)
Bradycardia, bronchospasm, chest pain
Inhaled (preferred; Note variable absorption likely)
0.2-0.3 ml/min of 10-20 μg/ml nebulized into inspiratory limb of ventilator circuit (30-40 ng/kg/min)
As above but less hypotension and improved oxygenation compared with intravenous use
2.5-5 μg 6-9 times/day, 1 mg/ml milrinone into the ventilator circuit at 0.2-0.3 ml/min for 10-20 minutes
As above and bronchospasm
5-80 ppm continuously
Less systemic hypotension than with IV milrinone
15-30 seconds (5 minutes)
Methemoglobinemia; withdrawal PH
ORAL (rarely in ICU)
62.5-125 mg b.d.
Liver-function test abnormalities; drug interactions; edema
0.25-0.75 mg/kg 4 hrly
As above; less hypotension and hypoxemia in stable patients
Pulmonary vasodilator therapy
Specific pulmonary vasodilators may be useful both to reduce RV afterload and to manipulate hypoxic vasoconstriction in patients with severe hypoxia. Agents are classically subdivided according to their action on the cyclic GMP, prostacyclin, or endothelin pathways . In the nonacute setting, these agents also target remodeling of"resistance" pulmonary vessels and have revolutionized the care of patients with PAH . Importantly, however, the management with pulmonary vasodilators in chronic PH patients differs in several ways from that with acute pulmonary vascular dysfunction, notably in terms of rapid changes in RV volume status, and potential adverse hemodynamic effects of nonselective pulmonary vasodilators in unstable patients.
Pulmonary vasodilators should be used after optimization of RV perfusion and CO. Systemic administration of pulmonary vasodilators may reduce systemic blood pressure , potentially reducing RV preload and worsening RV ischemia . Exclusion of a fixed elevated pulmonary venous pressure is important, as increased transpulmonary flow may precipitate pulmonary edema [203, 204]. Furthermore, nonselective actions of vasodilators may result in worsening ventilation/perfusion (V/Q) matching . This risk is reduced with the use of inhaled pulmonary vasodilators, with which the agent will reach vessels in only ventilated lung units .
Adenosine increases intracellular cAMP via A2 receptor agonism , and when administered intravenously, acts as a potent selective pulmonary vasodilator because of its rapid endothelial metabolism . It has been used as a therapy for adult PH in some settings, including after cardiac surgery , but may elevate LV end-diastolic pressure  and cause bradycardia and bronchospasm . It is currently therefore recommended as an alternative to NO and prostacyclin in dynamic vasoreactivity studies rather than as treatment for PH .
Inhaled nitric oxide
Inhaled nitric oxide (NO) is a potent pulmonary vasodilator with a short half-life due to rapid inactivation by hemoglobin. This minimizes systemic vasodilatation, although it necessitates continuous delivery into the ventilator circuit . NO selectively reduces PVR and improves CO in PAH , secondary PH [205, 213, 214], acute PE [215, 216], ischemic RV dysfunction [217, 218], and postsurgical PH [202, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234]. NO also improves oxygenation , RVEF, and reduces vasopressor requirements in PH after cardiac surgery , especially in patients with higher baseline PVR , with no augmented effect seen at doses above 10 ppm in these patients . Use of NO (or inhaled PGI2) after mitral valve replacement surgery results in easier weaning from cardiopulmonary bypass and shorter ICU stays [239, 240].
NO has been shown to reduce PVR and improve CO in several studies in patients with acute RV failure due to ARDS [79, 241, 242, 243, 244, 245, 246] and to improve oxygenation at lower doses than the RV effects . Administration of NO does need to be continuous for PVR reduction, and a potential exists for worsening oxygenation at excessive doses . The reduction in RV afterload, however, does not correlate with clinical-outcome benefits [249, 250, 251]. Similarly, despite short-term improvements in oxygenation in ARDS , no studies show a survival benefit [249, 250, 253, 254, 255, 256, 257].
NO provides synergistic pulmonary vasodilatation with intravenous prostacyclin , inhaled iloprost , and oral sildenafil [260, 261]. Limitations include accumulation of toxic metabolites, although this is not usually a clinically significant problem . Rebound PH with RV dysfunction may occur after weaning from NO [262, 263, 264], which may be reduced with PDE5 inhibitors [265, 266, 267, 268, 269, 270].
Prostanoids include prostaglandin-I2 (prostacyclin, PGI2) and its analogues, (iloprost) and prostaglandin-E1 (alprostadil, PGE1). An important difference between their formulations is their resulting half-life (Table 6). Prostacyclin is a potent systemic and pulmonary vasodilator, with antiplatelet  and antiproliferative effects . In PAH, these agents reduce PVR, increase CO, and improve clinical outcomes [273, 274, 275, 276, 277, 278, 279], and are used in patients with NYHA III-IV symptoms .
The use of prostanoids is most commonly described in ICU after cardiac surgery or transplantation. Intravenous prostacyclin [18, 280], PGE1 [281, 282, 283, 284, 285], inhaled prostacyclin [223, 286, 287, 288, 289, 290], and iloprost [291, 292, 293, 294, 295, 296, 297] all reduce PVR and improve RV performance in these settings, with inhaled agents being most selective. Intravenous PGE1 may cause marked desaturation in patients with lung disease . Inhaled prostacyclin has short-term equivalence to NO , and inhaled iloprost has been shown to be even more effective than NO at acutely reducing PVR and augmenting CO in PH after CPB  and in PAH . Inhaled PGI2 also acutely improves pulmonary hemodynamics after acute massive PE . Although PGI2 impairs platelet aggregation, clinical bleeding was not increased in one study . The potential anticoagulant effect should be remembered, however, especially in patients after surgery and receiving concomitant heparin.
In ARDS, intravenous prostacyclin reduces PVR and improves RV function, although it may increase intrapulmonary shunt . Inhaled prostacyclin [302, 303, 304, 305] and inhaled PGE1  improve oxygenation and reduce PVR in ARDS, with minimal effects on SVR. NO and intravenous PGI2 have been combined in ARDS with effective reduction of PVR without adverse effects .
GRADE RECOMMENDATION 7
Based on mostly moderate-quality evidence (see Additional file 1), the following STRONG recommendation is made: pulmonary vasodilators reduce PVR, improve CO and oxygenation, and may be useful when PH and RV dysfunction are present, notably after cardiac surgery.
Based on mostly moderate-quality evidence (see Additional file 1), the ICU side-effect profile of intravenous pulmonary vasodilators may be less favorable than that of inhaled agents. The following STRONG recommendation is therefore made: Consideration should be given to the use of inhaled rather than systemic agents when systemic hypotension is likely, and concomitant vasopressor use should be anticipated.
Based on mostly high-quality evidence (see Additional file 1), the following STRONG recommendation is made: give consideration for the use of NO as a short-term therapy to improve oxygenation indices but not outcome in patients with ARDS. Based on low-quality evidence (see Additional file 1), a WEAK recommendation is made that pulmonary vasodilators may also be useful treat PH associated with RV dysfunction in ARDS.
Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: Oral sildenafil may reduce PVR and facilitate weaning from NO after cardiac surgery in selected patients with PH, without adverse effects on systemic blood pressure in well-selected patients.
This encompasses RV "protective" strategies to avoid factors (Table 3) that may further increase PVR. Mechanical devices are also increasingly used to give a failing RV a bridge to recovery or transplantation.
Important variables that may reduce pulmonary blood flow during ventilation include hypoxia, hypercapnia, and compression of the pulmonary vasculature at the extremes of lung volumes (Figure 4). Acute hypoxia leading to hypoxic pulmonary vasoconstriction is well described  and may be augmented by many factors, including acidosis . Acute hypercapnia also leads to pulmonary vasoconstriction [328, 329], although this may be attenuated with NO , and, when associated with high PEEP, leads to RV dilatation and reduced cardiac output in severe ARDS [328, 329]. A reduction in pulmonary blood flow occurs both at low volumes, such as in areas of atelectasis, and at high lung volumes, such as with increased airway plateau pressure (Pplat): Increased RV afterload, reduced venous return, and acute RV dysfunction may result . Both atelectasis and ventilation at high lung volumes should therefore be avoided in patients with RV dysfunction.
Before the era of protective ventilatory strategies in ARDS, the incidence of acute RV failure was 60%  and has since decreased to 10% to 25% . This is thought to reflect the change in ventilatory practice: lower Pplat reduces the incidence of RV failure . Prone ventilation may also reduce Pplat and pCO2 sufficiently to improve acute RV failure . In ARDS, transition to high-frequency oscillation leads to an increase in CVP and a minor decrease in cardiac output due to preload reduction , and RV function may decrease during recruitment maneuvers . In children after Fontan procedures, the hemodynamic effects of negative-pressure ventilation (NPV) are nicely illustrated by measuring pulmonary blood flow: after a switch from conventional intermittent positive pressure ventilation (IPPV) to NPV by using cuirass ventilation, pulmonary blood flow, stroke volume, and cardiac output increased up to 50%, and decreased to baseline when IPPV was reinstituted [337, 338].
Mechanical support for the RV may be appropriate in reversible settings or as a bridge to definitive treatment. RV-assist devices (RVADs) may be used in primary RV dysfunction  and have been used with coexisting PH [340, 341]. There is, however, concern that pulsatile devices may cause pulmonary microcirculatory damage in PH [342, 343]. A pumpless "lung assist" device has been used in patients bridging to transplant . Extracorporeal membrane oxygenation (ECMO) has been used in severe PH [345, 346, 347, 348], as a bridge to transplant [349, 350], and after endarterectomy  or massive PE [352, 353, 354, 355]. Intraaortic balloon counterpulsation (IABP) has been used for RV failure after CPB  and transplantation , thought to improve CO by augmenting left coronary flow rather than by direct RV effects . Atrial septostomy creates a right-to-left shunt that improves left atrial filling and LV function while reducing RV end-diastolic pressure and improving RV contractility. It is sometimes used as a bridge to transplantation in severe PAH , although not in patients with very severe RV failure .
GRADE RECOMMENDATION 8
Based on mostly very-low-quality evidence, the following WEAK recommendation is made: Mechanical therapies including ECMO and IABP may have a role as rescue therapies in reversible pulmonary vascular dysfunction or while awaiting definitive treatment.
Pulmonary vascular and right ventricular dysfunction may complicate many ICU illnesses: the diagnosis may be difficult, and the acute management, challenging. Their presence is associated with a worse outcome. This review highlights that some recommendations can be made, despite limitations of the GRADE analysis. However, we do consider that "weak GRADE recommendations" could be interpreted as "management suggestions" and treated with appropriate caution. A further limitation is that several pathologies have been grouped together as one syndrome, although this relates to both the rarity of the syndrome and the lack of high-quality evidence: further research is desperately needed. In particular, only then will we learn whether PAH-targeted therapy such as use of PDE5 inhibitors or endothelin-receptor antagonists, so effective in idiopathic PAH, have a role in the ICU setting.
Pulmonary hypertension (PH) and associated right ventricular (RV) failure are associated with worse outcomes in critical care, and because of nonspecific presenting symptoms and signs, may be difficult to recognize: echocardiography is a very useful initial test, and invasive monitoring may be helpful in some cases for more continuous monitoring and accurate measurement of pulmonary vascular resistance.
Volume loading of the right ventricle may worsen its performance: all fluid challenges should be closely monitored.
It is essential to maintain adequate aortic root pressure to prevent the onset of RV ischemia. Vasopressors are useful in this setting, including low-dose norepinephrine as a first-line agent. Low-dose vasopressin may also be useful in some resistant cases but has adverse myocardial effects at higher doses. Potentially useful inotropes in RV failure include dobutamine and those with additional pulmonary vasodilating effects, including PDE III inhibitors, although co-administration with pressors is often necessary. The effects of any vasoactive drug may be unpredictable in an individual and require close clinical observation of circulatory performance, potentially assisted by echocardiography.
Pulmonary vasodilators are useful to reduce RV afterload in several ICU settings, including PH and RV failure after cardiac surgery. Systemic administration may worsen systemic hemodynamics and oxygenation because of ventilation-perfusion mismatching.
The use of mechanical therapies to manage acute PH and enhance RV performance is expanding, although with evidence currently limited to case series, and may be useful in experienced centers to ameliorate RV failure while awaiting definitive therapy.
SJB is grateful for the support of the UK NIHR Biomedical Research Centre Scheme.
- 12.Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM: Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006, 174: 1034-1041. 10.1164/rccm.200604-547OC.PubMedGoogle Scholar
- 13.Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18: 1440-1463. 10.1016/j.echo.2005.10.005.PubMedGoogle Scholar
- 14.Le Tulzo Y, Seguin P, Gacouin A, Camus C, Suprin E, Jouannic I, Thomas R: Effects of epinephrine on right ventricular function in patients with severe septic shock and right ventricular failure: a preliminary descriptive study. Intensive Care Med. 1997, 23: 664-670. 10.1007/s001340050391.PubMedGoogle Scholar
- 19.Sibbald WJ, Paterson NA, Holliday RL, Anderson RA, Lobb TR, Duff JH: Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest. 1978, 73: 583-591. 10.1378/chest.73.5.583.PubMedGoogle Scholar
- 24.Vieillard-Baron A, Schmitt JM, Augarde R, Fellahi JL, Prin S, Page B, Beauchet A, Jardin F: Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med. 2001, 29: 1551-1555. 10.1097/00003246-200108000-00009.PubMedGoogle Scholar
- 25.Vieillard-Baron A, Page B, Augarde R, Prin S, Qanadli S, Beauchet A, Dubourg O, Jardin F: Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med. 2001, 27: 1481-1486. 10.1007/s001340101032.PubMedGoogle Scholar
- 36.Price LC, Montani D, Jais X, Dick JR, Simonneau G, Sitbon O, Mercier FJ, Humbert M: Non-cardiothoracic non-obstetric surgery in mild-moderate pulmonary hypertension: perioperative management of 28 consecutive individual cases. Eur Respir J. 2010, 35: 1294-1302. 10.1183/09031936.00113009.PubMedGoogle Scholar
- 37.Bonnin M, Mercier FJ, Sitbon O, Roger-Christoph S, Jais X, Humbert M, Audibert F, Frydman R, Simonneau G, Benhamou D: Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005, 102: 1133-1137. 10.1097/00000542-200506000-00012. discussion 1135A-1136APubMedGoogle Scholar
- 42.Price LC, Montani D, Jais X, Dick JR, Simonneau G, Sitbon O, Mercier FJ, Humbert M: Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J. 35: 1294-1302. 10.1183/09031936.00113009.Google Scholar
- 51.Fellahi JL, Valtier B, Beauchet A, Bourdarias JP, Jardin F: Does positive end-expiratory pressure ventilation improve left ventricular function? A comparative study by transesophageal echocardiography in cardiac and noncardiac patients. Chest. 1998, 114: 556-562. 10.1378/chest.114.2.556.PubMedGoogle Scholar
- 54.Ricciardi MJ, Bossone E, Bach DS, Armstrong WF, Rubenfire M: Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing. Chest. 1999, 116: 1218-1223. 10.1378/chest.116.5.1218.PubMedGoogle Scholar
- 61.Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I, De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M, Poldermans D, Ranucci M, Karpati PC, Wouters P, Seeberger M, Schmid ER, Weder W, Follath F: Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care. 2010, 14: 201-10.1186/cc8153.PubMedCentralPubMedGoogle Scholar
- 64.Gadhinglajkar S, Sreedhar R, Jayakumar K, Misra M, Ganesh S, Panicker V: Intra-operative assessment of biventricular function using trans-esophageal echocardiography pre/post-pulmonary thromboembolectomy in patient with chronic thromboembolic pulmonary hypertension. Ann Card Anaesth. 2009, 12: 140-145. 10.4103/0971-9784.53449.PubMedGoogle Scholar
- 66.Currie PJ, Seward JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, Reeder GS, Nishimura RA, Tajik AJ: Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985, 6: 750-756. 10.1016/S0735-1097(85)80477-0.PubMedGoogle Scholar
- 69.Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartiere JM, Chavelas C, Bonnin F, Stievenart JL, Solal AC: Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. Intensive Care Med. 2007, 33: 286-292. 10.1007/s00134-006-0482-1.PubMedGoogle Scholar
- 72.Clark BJ, Brown NJ, Moss M, Bull TM: Increased serum BNP concentrations are associated with pulmonary vascular dysfunction in patients with acute lung injury. Am J Respir Crit Care Med. 2010, 181: A2582-Google Scholar
- 74.Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA: Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993, 341: 507-511. 10.1016/0140-6736(93)90274-K.PubMedGoogle Scholar
- 82.Gan CT, Lankhaar JW, Marcus JT, Westerhof N, Marques KM, Bronzwaer JG, Boonstra A, Postmus PE, Vonk-Noordegraaf A: Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2006, 290: H1528-H1533.PubMedGoogle Scholar
- 94.Schneider AJ, Teule GJ, Groeneveld AB, Nauta J, Heidendal GA, Thijs LG: Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: a combined hemodynamic and radionuclide study. Am Heart J. 1988, 116: 103-112. 10.1016/0002-8703(88)90256-6.PubMedGoogle Scholar
- 105.Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Bachetoni A, D'Alessandro M, Van Aken H, Pietropaoli P, Westphal M: Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009, 13: R130-10.1186/cc7990.PubMedCentralPubMedGoogle Scholar
- 115.Jeon Y, Ryu JH, Lim YJ, Kim CS, Bahk JH, Yoon SZ, Choi JY: Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg. 2006, 29: 952-956. 10.1016/j.ejcts.2006.02.032.PubMedGoogle Scholar
- 116.Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, Akashi H, Aoyagi S: Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg. 2007, 6: 715-719. 10.1510/icvts.2007.159624.PubMedGoogle Scholar
- 121.Torgersen C, Dunser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med. 2010, 36: 57-65. 10.1007/s00134-009-1630-1.PubMedGoogle Scholar
- 124.Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997, 96: II-286-II-290.Google Scholar
- 128.Jain RL, Horn EM: Peripheral vasodilation complicated by pulmonary hypertension: a role for vasopressin. Am J Respir Crit Care Med. 2008, 177: A919-Google Scholar
- 135.Mols P, Hallemans R, Van Kuyk M, Melot C, Lejeune P, Ham H, Vertongen F, Naeije R: Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension. Ann Surg. 1984, 199: 176-181. 10.1097/00000658-198402000-00008.PubMedCentralPubMedGoogle Scholar
- 136.Migotto WH, Dahi H: Effects of vasopressin on hemodynamics in cardiogenic shock. Chest. 2005, 128: 168S-Google Scholar
- 150.Acosta F, Sansano T, Palenciano CG, Falcon L, Domenech P, Robles R, Bueno FS, Ramirez P, Parrilla P: Effects of dobutamine on right ventricular function and pulmonary circulation in pulmonary hypertension during liver transplantation. Transplant Proc. 2005, 37: 3869-3870. 10.1016/j.transproceed.2005.10.045.PubMedGoogle Scholar
- 153.Vizza CD, Rocca GD, Roma AD, Iacoboni C, Pierconti F, Venuta F, Rendina E, Schmid G, Pietropaoli P, Fedele F: Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care. 2001, 5: 355-361. 10.1186/cc1069.PubMedCentralPubMedGoogle Scholar
- 164.Eichhorn EJ, Konstam MA, Weiland DS, Roberts DJ, Martin TT, Stransky NB, Salem DN: Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1987, 60: 1329-1333. 10.1016/0002-9149(87)90616-3.PubMedGoogle Scholar
- 169.Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynands JE: Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth. 1992, 6: 542-553. 10.1016/1053-0770(92)90096-P.PubMedGoogle Scholar
- 178.Haraldssons A, Kieler-Jensen N, Ricksten SE: The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg. 2001, 93: 1439-1445. 10.1097/00000539-200112000-00018. table of contentsGoogle Scholar
- 180.Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002, 360: 196-202. 10.1016/S0140-6736(02)09455-2.PubMedGoogle Scholar
- 181.Barraud D, Faivre V, Damy T, Welschbillig S, Gayat E, Heymes C, Payen D, Shah AM, Mebazaa A: Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med. 2007, 35: 1376-1382. 10.1097/01.CCM.0000261889.18102.84.PubMedGoogle Scholar
- 183.Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM: Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther. 1997, 61: 596-607. 10.1016/S0009-9236(97)90139-9.PubMedGoogle Scholar
- 185.Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure: study investigators. Circulation. 2000, 102: 2222-2227.PubMedGoogle Scholar
- 191.Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, Lemm H, Heinroth K, Soeffker G, Winkler M, Werdan K, Buerke M: Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med. 2009, 37: 3017-3023. 10.1097/CCM.0b013e3181b0314a.PubMedGoogle Scholar
- 195.Morelli A, Teboul JL, Maggiore SM, Vieillard-Baron A, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Carbone I, Tritapepe L, Pietropaoli P, Westphal M: Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med. 2006, 34: 2287-2293. 10.1097/01.CCM.0000230244.17174.4F.PubMedGoogle Scholar
- 198.Kleber FX, Bollmann T, Borst MM, Costard-Jackle A, Ewert R, Kivikko M, Petterson T, Pohjanjousi P, Sonntag S, Wikstrom G: Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol. 2009, 49: 109-115.PubMedGoogle Scholar
- 199.Raper R: FMM: The heart and circulation in sepsis. Balliere's Clin Anaesthesiol. 1990, 4: 333-355. 10.1016/S0950-3501(05)80290-9.Google Scholar
- 201.Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G: Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J. 2009, 34: 1219-1263. 10.1183/09031936.00139009.PubMedGoogle Scholar
- 211.Oliveira EC, Ribeiro AL, Amaral CF: Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. Respir Med. 104: 606-611. 10.1016/j.rmed.2009.11.010.Google Scholar
- 226.Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, Marelli D, Beygui R, Shemin R, Watson L, Vartapetian I, Ardehali A: A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg. 2009, 138: 1417-1424. 10.1016/j.jtcvs.2009.04.063.PubMedGoogle Scholar
- 233.Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann Hein HA, Molmenti H, Levy M, Goldstein R, Ausloos K, East C, Fasola C, Jung G, Escobar J, Klintmalm G: Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. Transplant Proc. 2001, 33: 1332-10.1016/S0041-1345(00)02807-4.PubMedGoogle Scholar
- 236.Solina A, Papp D, Ginsberg S, Krause T, Grubb W, Scholz P, Pena LL, Cody R: A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth. 2000, 14: 12-17. 10.1016/S1053-0770(00)90048-X.PubMedGoogle Scholar
- 239.Fattouch K, Sbraga F, Sampognaro R, Bianco G, Gucciardo M, Lavalle C, Vizza CD, Fedele F, Ruvolo G: Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown). 2006, 7: 119-123. 10.2459/01.JCM.0000203850.97890.fe.Google Scholar
- 240.Healy DG, Veerasingam D, McHale J, Luke D: Successful perioperative utilisation of inhaled nitric oxide in mitral valve surgery. J Cardiovasc Surg (Torino). 2006, 47: 217-220.Google Scholar
- 246.Bigatello LM, Hurford WE, Kacmarek RM, Roberts JD, Zapol WM: Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome: effects on pulmonary hemodynamics and oxygenation. Anesthesiology. 1994, 80: 761-770. 10.1097/00000542-199404000-00007.PubMedGoogle Scholar
- 248.Gerlach H, Keh D, Semmerow A, Busch T, Lewandowski K, Pappert DM, Rossaint R, Falke KJ: Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 2003, 167: 1008-1015. 10.1164/rccm.2108121.PubMedGoogle Scholar
- 249.Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, Davis K, Hyers TM, Papadakos P: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial: inhaled nitric oxide in ARDS study group. Crit Care Med. 1998, 26: 15-23. 10.1097/00003246-199801000-00011.PubMedGoogle Scholar
- 256.Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, Elstad MR, Campbell EJ, Troyer BE, Whatley RE, Liou TG, Samuelson WM, Carveth HJ, Hinson DM, Morris SE, Davis BL, Day RW: Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med. 1998, 157: 1372-1380.PubMedGoogle Scholar
- 260.Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005, 127: 1647-1653. 10.1378/chest.127.5.1647.PubMedGoogle Scholar
- 261.Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002, 90: 677-680. 10.1016/S0002-9149(02)02586-9.PubMedGoogle Scholar
- 269.Klodell CT, Morey TE, Lobato EB, Aranda JM, Staples ED, Schofield RS, Hess PJ, Martin TD, Beaver TM: Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007, 83: 68-71. 10.1016/j.athoracsur.2006.08.051. discussion 71PubMedGoogle Scholar
- 271.Moncada S, Gryglewski RJ, Bunting S, Vane JR: A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 1976, 12: 715-737. 10.1016/0090-6980(76)90048-4.PubMedGoogle Scholar
- 274.Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn DS, Shortino D, Crow JW: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996, 334: 296-302. 10.1056/NEJM199602013340504.PubMedGoogle Scholar
- 275.Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002, 347: 322-329. 10.1056/NEJMoa020204.PubMedGoogle Scholar
- 277.Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH study group. J Am Coll Cardiol. 2000, 35: 176-182. 10.1016/S0735-1097(99)00494-5.PubMedGoogle Scholar
- 283.Radovancevic B, Vrtovec B, Thomas CD, Croitoru M, Myers TJ, Radovancevic R, Khan T, Massin EK, Frazier OH: Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant. 2005, 24: 690-695. 10.1016/j.healun.2004.04.016.PubMedGoogle Scholar
- 287.Hache M, Denault AY, Belisle S, Couture P, Babin D, Tetrault F, Guimond JG: Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth. 2001, 48: 924-929. 10.1007/BF03017361.PubMedGoogle Scholar
- 288.De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, Zanaboni PB, Moazami N, Smith JR: Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004, 127: 1058-1067. 10.1016/j.jtcvs.2003.11.035.PubMedGoogle Scholar
- 292.Rex S, Schaelte G, Metzelder S, Flier S, de Waal EE, Autschbach R, Rossaint R, Buhre W: Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand. 2008, 52: 65-72. 10.1111/j.1399-6576.2007.01476.x.PubMedGoogle Scholar
- 293.Yurtseven N, Karaca P, Uysal G, Ozkul V, Cimen S, Tuygun AK, Yuksek A, Canik S: A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann Thorac Cardiovasc Surg. 2006, 12: 319-323.PubMedGoogle Scholar
- 296.Sablotzki A, Hentschel T, Gruenig E, Schubert S, Friedrich I, Muhling J, Dehne MG, Czeslick E: Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg. 2002, 22: 746-752. 10.1016/S1010-7940(02)00488-8.PubMedGoogle Scholar
- 298.Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, Zuk J, Piepenbrock S, Struber M: Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth. 2008, 22: 406-413. 10.1053/j.jvca.2007.10.015.PubMedGoogle Scholar
- 307.Kuhlen R, Walbert E, Frankel P, Thaden S, Behrendt W, Rossaint R: Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndrome. Intensive Care Med. 1999, 25: 752-754. 10.1007/s001340050941.PubMedGoogle Scholar
- 310.Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002, 105: 2398-2403. 10.1161/01.CIR.0000016641.12984.DC.PubMedGoogle Scholar
- 315.Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED: Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007, 116: 238-248. 10.1161/CIRCULATIONAHA.106.655266.PubMedGoogle Scholar
- 317.De Santo LS, Mastroianni C, Romano G, Amarelli C, Marra C, Maiello C, Galdieri N, Della Corte A, Cotrufo M, Caianiello G: Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc. 2008, 40: 2015-2018. 10.1016/j.transproceed.2008.05.055.PubMedGoogle Scholar
- 321.Aubin MC, Laurendeau S, Mommerot A, Lamarche Y, Denault A, Carrier M, Perrault LP: Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol. 2008, 51: 11-17. 10.1097/FJC.0b013e3181598279.PubMedGoogle Scholar
- 322.Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002, 360: 895-900. 10.1016/S0140-6736(02)11024-5.PubMedGoogle Scholar
- 329.Mekontso Dessap A, Charron C, Devaquet J, Aboab J, Jardin F, Brochard L, Vieillard-Baron A: Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. Intensive Care Med. 2009, 35: 1850-1858. 10.1007/s00134-009-1569-2.PubMedCentralPubMedGoogle Scholar
- 330.Puybasset L, Stewart T, Rouby JJ, Cluzel P, Mourgeon E, Belin MF, Arthaud M, Landault C, Viars P: Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology. 1994, 80: 1254-1267. 10.1097/00000542-199406000-00013.PubMedGoogle Scholar
- 344.Strueber M, Hoeper MM, Fischer S, Cypel M, Warnecke G, Gottlieb J, Pierre A, Welte T, Haverich A, Simon AR, Keshavjee S: Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am J Transplant. 2009, 9: 853-857. 10.1111/j.1600-6143.2009.02549.x.PubMedGoogle Scholar
- 349.Gregoric ID, Chandra D, Myers TJ, Scheinin SA, Loyalka P, Kar B: Extracorporeal membrane oxygenation as a bridge to emergency heart-lung transplantation in a patient with idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2008, 27: 466-468. 10.1016/j.healun.2008.01.016.PubMedGoogle Scholar
- 351.Berman M, Tsui S, Vuylsteke A, Snell A, Colah S, Latimer R, Hall R, Arrowsmith JE, Kneeshaw J, Klein AA, Jenkins DP: Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy. Ann Thorac Surg. 2008, 86: 1261-1267. 10.1016/j.athoracsur.2008.06.037.PubMedGoogle Scholar
- 359.Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN, Auger WR, Fedullo PF, Smith CM, Kriett JM, Jamieson SW: Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol. 1999, 84: 682-686. 10.1016/S0002-9149(99)00416-6.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.